Stock Track | agilon health Plunges 17.63% in Pre-Market as Weak 2025 Guidance Overshadows Q4 Growth

Stock Track

Feb 26, 2025

agilon health, inc. (AGL) experienced a significant pre-market plunge of 17.63% on Wednesday, following the company's mixed fourth-quarter 2024 earnings results and disappointing guidance for the upcoming fiscal year 2025.

While the healthcare services company reported strong revenue growth of 44% year-over-year in Q4 2024, reaching $1.52 billion, its earnings metrics fell short of expectations. agilon health reported an adjusted loss per share of $0.26, wider than analysts' estimates, and an adjusted EBITDA loss of $83.97 million, significantly lagging projections.

However, the primary concern for investors appears to be the company's weak outlook for fiscal 2025. agilon health provided revenue growth guidance of just -2.2% year-over-year at the midpoint, a sharp deceleration from the impressive 40.7% growth achieved in 2024. Additionally, the projected 2025 adjusted EBITDA guidance of -$75 million fell short of expectations, highlighting continued profitability challenges amid what management termed a "challenging Medicare Advantage environment."

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1147255696"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1147255696\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1147255696?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-26 20:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1147255696","market":"us","top_or_hot":-1,"title":"Stock Track | agilon health Plunges 17.63% in Pre-Market as Weak 2025 Guidance Overshadows Q4 Growth","media":"Stock Track","content":"<p>agilon health, inc. (AGL) experienced a significant pre-market plunge of 17.63% on Wednesday, following the company's mixed fourth-quarter 2024 earnings results and disappointing guidance for the upcoming fiscal year 2025.</p>\n\n<p>While the healthcare services company reported strong revenue growth of 44% year-over-year in Q4 2024, reaching $1.52 billion, its earnings metrics fell short of expectations. agilon health reported an adjusted loss per share of $0.26, wider than analysts' estimates, and an adjusted EBITDA loss of $83.97 million, significantly lagging projections.</p>\n\n<p>However, the primary concern for investors appears to be the company's weak outlook for fiscal 2025. agilon health provided revenue growth guidance of just -2.2% year-over-year at the midpoint, a sharp deceleration from the impressive 40.7% growth achieved in 2024. Additionally, the projected 2025 adjusted EBITDA guidance of -$75 million fell short of expectations, highlighting continued profitability challenges amid what management termed a \"challenging Medicare Advantage environment.\"</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | agilon health Plunges 17.63% in Pre-Market as Weak 2025 Guidance Overshadows Q4 Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | agilon health Plunges 17.63% in Pre-Market as Weak 2025 Guidance Overshadows Q4 Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-26 20:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>agilon health, inc. (AGL) experienced a significant pre-market plunge of 17.63% on Wednesday, following the company's mixed fourth-quarter 2024 earnings results and disappointing guidance for the upcoming fiscal year 2025.</p>\n\n<p>While the healthcare services company reported strong revenue growth of 44% year-over-year in Q4 2024, reaching $1.52 billion, its earnings metrics fell short of expectations. agilon health reported an adjusted loss per share of $0.26, wider than analysts' estimates, and an adjusted EBITDA loss of $83.97 million, significantly lagging projections.</p>\n\n<p>However, the primary concern for investors appears to be the company's weak outlook for fiscal 2025. agilon health provided revenue growth guidance of just -2.2% year-over-year at the midpoint, a sharp deceleration from the impressive 40.7% growth achieved in 2024. Additionally, the projected 2025 adjusted EBITDA guidance of -$75 million fell short of expectations, highlighting continued profitability challenges amid what management termed a \"challenging Medicare Advantage environment.\"</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AGL","symbol_name":"agilon health, inc.","start_time":0,"source_url":"","article_id":"1147255696","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1147255696","pubTimestamp":1740571407,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"agilon health, inc.  experienced a significant pre-market plunge of 17.63% on Wednesday, following the company's mixed fourth-quarter 2024 earnings results and disappointing guidance for the upcoming fiscal year 2025.While the healthcare services company reported strong revenue growth of 44% year-over-year in Q4 2024, reaching $1.52 billion, its earnings metrics fell short of expectations. agilon health reported an adjusted loss per share of $0.26, wider than analysts' estimates, and an adjusted","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AGL":"agilon health, inc."},"translate_title":"股票赛道agilon health盘前暴跌17.63%，2025年指引疲弱掩盖了第四季度增长","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AGL":1},"content_text":"agilon health, inc. (AGL) experienced a significant pre-market plunge of 17.63% on Wednesday, following the company's mixed fourth-quarter 2024 earnings results and disappointing guidance for the upcoming fiscal year 2025.\nWhile the healthcare services company reported strong revenue growth of 44% year-over-year in Q4 2024, reaching $1.52 billion, its earnings metrics fell short of expectations. agilon health reported an adjusted loss per share of $0.26, wider than analysts' estimates, and an adjusted EBITDA loss of $83.97 million, significantly lagging projections.\nHowever, the primary concern for investors appears to be the company's weak outlook for fiscal 2025. agilon health provided revenue growth guidance of just -2.2% year-over-year at the midpoint, a sharp deceleration from the impressive 40.7% growth achieved in 2024. Additionally, the projected 2025 adjusted EBITDA guidance of -$75 million fell short of expectations, highlighting continued profitability challenges amid what management termed a \"challenging Medicare Advantage environment.\"","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}